Last reviewed · How we verify
Placebo for Estradiol/Norethindrone Acetate
This is a placebo control formulation containing inert ingredients with no active pharmacological effect, used as a comparator in clinical trials of Estradiol/Norethindrone Acetate.
This is a placebo control formulation containing inert ingredients with no active pharmacological effect, used as a comparator in clinical trials of Estradiol/Norethindrone Acetate. Used for Control arm in clinical trials of Estradiol/Norethindrone Acetate for menopausal symptom management.
At a glance
| Generic name | Placebo for Estradiol/Norethindrone Acetate |
|---|---|
| Sponsor | AbbVie |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Hormone Replacement Therapy |
| Phase | Phase 3 |
Mechanism of action
Placebo formulations are used in randomized controlled trials to establish the efficacy and safety of active pharmaceutical agents by providing an inert control arm. In this case, the placebo matches the appearance and administration route of the active Estradiol/Norethindrone Acetate combination but contains no hormonal components, allowing researchers to isolate the true therapeutic effects of the hormone replacement therapy from psychological or expectancy effects.
Approved indications
- Control arm in clinical trials of Estradiol/Norethindrone Acetate for menopausal symptom management
Common side effects
Key clinical trials
- Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (PHASE3)
- A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain (PHASE3)
- Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PHASE3)
- Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448) (PHASE3)
- Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids. (PHASE3)
- LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PHASE3)
- LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PHASE3)
- An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Estradiol/Norethindrone Acetate CI brief — competitive landscape report
- Placebo for Estradiol/Norethindrone Acetate updates RSS · CI watch RSS
- AbbVie portfolio CI